Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure

Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure

Aim. To assess cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and achieving the target indicator "reduction of cardiovascular mortality" of the State Program "Health Development" in patients with heart failure (H...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Zhuravleva, S. N. Tereshchenko, F. N. Paleev, Yu. V. Gagarina, E. A. Shabalina
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2023-12-01
Series:Российский кардиологический журнал
Subjects:
heart failure
myocardial infarction
cerebrovascular accident
target indicator
cardiovascular mortality
state program "health development"
valsartan+sacubitril
dapagliflozin
empagliflozin
Online Access:https://russjcardiol.elpub.ru/jour/article/view/5711
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items